Danemarca - daneză - Lægemiddelstyrelsen (Danish Medicines Agency)

roche a/s - ceftriaxonnatrium - pulver til infusionsvæske, opløsning - 2 g

Danemarca - daneză - Lægemiddelstyrelsen (Danish Medicines Agency)

paranova danmark a/s - nicotin - depotplastre - 21 mg/24 timer

Danemarca - daneză - Lægemiddelstyrelsen (Danish Medicines Agency)

macure pharma aps - melphalanhydrochlorid - pulver og solvens til injektions- /infusionsvæske, opløsning - 50 mg

Danemarca - daneză - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - vigabatrin - granulat til oral opløsning - 500 mg

Danemarca - daneză - Lægemiddelstyrelsen (Danish Medicines Agency)

paranova danmark a/s - vigabatrin - granulat til oral opløsning - 500 mg

Danemarca - daneză - Lægemiddelstyrelsen (Danish Medicines Agency)

nordic prime aps - adrenalin - injektionsvæske, opløsning - 0,3 mg/dosis

Danemarca - daneză - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - adrenalin - injektionsvæske, opløsning - 0,15 mg/dosis

Uniunea Europeană - daneză - EMA (European Medicines Agency)

sandoz pharmaceuticals d.d. - nelarabin - forløber t-celle lymfoblastisk leukæmi-lymfom - antineoplastiske midler - nelarabine er indiceret til behandling af patienter med t-celle akut lymfoblastær leukæmi (t-all) og t-celle lymphoblastic lymphoma (t-lbl), hvis sygdommen ikke har reageret eller har fået tilbagefald efter behandling med mindst to kemoterapi regimer. due to the small patient populations in these disease settings, the information to support these indications is based on limited data.

Uniunea Europeană - daneză - EMA (European Medicines Agency)

pierre fabre medicament - propranololhydrochlorid - hemangioma - betablokkende midler - hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy: , life- or function-threatening haemangioma,, ulcerated haemangioma with pain and/or lack of response to simple wound care measures,, haemangioma with a risk of permanent scars or disfigurement. , it is to be initiated in infants aged 5 weeks to 5 months.

Uniunea Europeană - daneză - EMA (European Medicines Agency)

pharmaand gmbh - peginterferon alfa-2a - hepatitis c, chronic; hepatitis b, chronic - immunostimulants, - chronic hepatitis b adult patients pegasys is indicated for the treatment of hepatitis b envelope antigen (hbeag)-positive or hbeag-negative chronic hepatitis b (chb) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (alt) and histologically verified liver inflammation and/or fibrosis (see sections 4. 4 og 5. paediatric patients 3 years of age and older pegasys is indicated for the treatment of hbeag-positive chb in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum alt levels. med hensyn til beslutningen om at indlede behandling hos pædiatriske patienter, se afsnit 4. 2, 4. 4 og 5. chronic hepatitis c adult patients pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis c (chc) in patients with compensated liver disease (see sections 4. 2, 4. 4 og 5. for at hepatitis c virus (hcv) genotype specifik aktivitet, se afsnit 4. 2 og 5. paediatric patients 5 years of age and older pegasys in combination with ribavirin is indicated for the treatment of chc in treatment-naïve children and adolescents 5 years of age and older who are positive for serum hcv-rna. når det besluttes at indlede behandling i barndommen, er det vigtigt at overveje, væksthæmning, der er fremkaldt af en kombination terapi. reversibilitet af væksthæmning er usikker. beslutningen om at behandling skal ske på grundlag af en individuel vurdering (se afsnit 4.